Improved sensitivity in BRAFV600E detection in combined tissue and extracellular vesicles-based liquid biopsy in melanoma.

García-Silva, Susana; Vico-Alonso, Cristina; Meyer, Lisa; Enderle, Daniel; Sanchez, J Aquiles; Onteniente, María Del Mar; Noerholm, Mikkel; Skog, Johan; Rodríguez-Peralto, José-Luis; Ortiz-Romero, Pablo-Luis; Peinado Selgas, Hector

Publication:
Improved sensitivity in BRAFV600E detection in combined tissue and extracellular vesicles-based liquid biopsy in melanoma.

dc.contributor.author	García-Silva, Susana
dc.contributor.author	Vico-Alonso, Cristina
dc.contributor.author	Meyer, Lisa
dc.contributor.author	Enderle, Daniel
dc.contributor.author	Sanchez, J Aquiles
dc.contributor.author	Onteniente, María Del Mar
dc.contributor.author	Noerholm, Mikkel
dc.contributor.author	Skog, Johan
dc.contributor.author	Rodríguez-Peralto, José-Luis
dc.contributor.author	Ortiz-Romero, Pablo-Luis
dc.contributor.author	Peinado Selgas, Hector
dc.contributor.funder	Asociación Española Contra el Cáncer
dc.contributor.funder	Grupo Español de Melanoma (HP)	es_ES
dc.contributor.funder	Fundación BBVA
dc.contributor.funder	Ministerio de Ciencia e Innovación. Centro de Excelencia Severo Ochoa (España)
dc.date.accessioned	2023-02-23T09:30:58Z
dc.date.available	2023-02-23T09:30:58Z
dc.date.issued	2023-02-15
dc.description	This study was approved by the institutional ethical review board (CEIC) of Hospital 12 de Octubre (Madrid, Spain) and institutional review board information is04.625 version September 26th2018 on Act 20/18 dated by November 13th2018. Written informed consent was obtained from all participants. Conflict of Interest StatementJohan Skog has patents for exosome-based technologies and is an employee and shareholder of Bio-techne. J. Aquiles Sanchez is an employee of Bio-techne. Lisa Meyer, Daniel Enderle and Mikkel Noerholm are former employees of Bio-techne. Authors declare no additional conflicts of interes	es_ES
dc.description.abstract	To the editor, cutaneous melanoma in its early stages is a curable disease by surgery of skin lesions. However, intermediate stages display variable outcomes. BRAF V600 mutations are the most frequent alterations in melanoma ocurring in 35-50% of patients ( Luke et al., 2017) and remain informative for guiding first-line treatment election ( Robert et al., 2019).	es_ES
dc.description.peerreviewed	No	es_ES
dc.description.sponsorship	We would like to thank Carmen María García, Sara Sánchez-Redondo, Vanesa Santos and Juan García-Agulló for technical support. This work has been funded by Fundación AECC (LABAE19027PEIN) (H.P.), Grupo Español de Melanoma (H.P.), Fundación BBVA (H.P.), FIS PI-17/00957 (P.L.O-R) and Centro de Excelencia “Severo Ochoa” (CEX2019-000891-S) (S.G-S.).	es_ES
dc.identifier.citation	J Invest Dermatol. 2023 Feb 15;S0022-202X(23)00091-X.	es_ES
dc.identifier.doi	10.1016/j.jid.2023.01.025	es_ES
dc.identifier.e-issn	1523-1747	es_ES
dc.identifier.journal	The Journal of investigative dermatology	es_ES
dc.identifier.pubmedID	36804405	es_ES
dc.identifier.uri	http://hdl.handle.net/20.500.12105/15538
dc.language.iso	eng	es_ES
dc.publisher	Elsevier
dc.relation.projectFECYT	info:eu-repo/grantAgreement/CEX2019-000891-S	es_ES
dc.relation.projectFIS	info:eu-repo/grantAgreement/ES/PI-17/00957	es_ES
dc.relation.publisherversion	https://doi.org/10.1016/j.jid.2023.01.025.	es_ES
dc.repisalud.institucion	CNIO	es_ES
dc.repisalud.orgCNIO	CNIO::Grupos de investigación::Grupo de Microambiente y Metástasis	es_ES
dc.rights.accessRights	open access	es_ES
dc.rights.license	Attribution-NonCommercial-NoDerivatives 4.0 Internacional	*
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/4.0/	*
dc.subject	BRAF	es_ES
dc.subject	Melanoma	es_ES
dc.subject	Biomarkers	es_ES
dc.subject	Oncology	es_ES
dc.subject	Tumors markers	es_ES
dc.subject	Cancer	es_ES
dc.title	Improved sensitivity in BRAFV600E detection in combined tissue and extracellular vesicles-based liquid biopsy in melanoma.	es_ES
dc.type	preprint	es_ES
dc.type.hasVersion	AM	es_ES
dspace.entity.type	Publication
relation.isAuthorOfPublication	f33d0f5a-ce2e-4874-a2d8-03c0974e8b1d
relation.isAuthorOfPublication.latestForDiscovery	f33d0f5a-ce2e-4874-a2d8-03c0974e8b1d
relation.isFunderOfPublication	453a1189-9bca-4be8-8d60-695f50fe028b
relation.isFunderOfPublication	8e968c1d-10f1-4a7d-acec-e92ae81c76a4
relation.isFunderOfPublication	9bec53f6-b1d2-4340-9f6b-91815956d602
relation.isFunderOfPublication.latestForDiscovery	453a1189-9bca-4be8-8d60-695f50fe028b
relation.isPublisherOfPublication	7d471502-7bd5-4f7a-90a4-8274382509ef
relation.isPublisherOfPublication.latestForDiscovery	7d471502-7bd5-4f7a-90a4-8274382509ef